Optimized tumor cryptic peptides: The basis for universal neoantigen-like tumor vaccines

Annals of Translational Medicine

Volumn 4, Issue 14, 2016, Pages

  Menez Jamet, Jeanne ^a   Gallou, Catherine ^a   Rougeot, Aude ^a   Kosmatopoulos, Kostas ^a  

^a Vaxon Biotech   (France)

Author keywords

Telomerase reverse transcriptase (TERT); Tumor associated antigens (TAA); Tumor specific antigens (TSA)

Indexed keywords

ANTIGEN LIKE TUMOR VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR CRYPTIC PEPTIDE; TUMOR VACCINE; UNCLASSIFIED DRUG; VX 001 PEPTIDE;

BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW;

EID: 85006226438     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.05.15     Document Type: Review

References (63)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
3. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
4. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.
5. Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
6. Moudgil KD, Sercarz EE. The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin Immunol Immunopathol 1994;73:283-9.
7. Yamada N, Oizumi S, Kikuchi E, et al. CD8+ tumorinfiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010;59:1543-9.
8. Oble DA, Loewe R, Yu P, et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009;9:3.
9. Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014;24:743-50.
10. Maby P, Tougeron D, Hamieh M, et al. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. Cancer Res 2015;75:3446-55.
11. Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015;125:3413-21.
12. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5.
13. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
14. Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015;348:803-8.
15. van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
16. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
17. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6.
18. Kalaora S, Barnea E, Merhavi-Shoham E, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016;7:5110-7.
19. Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015;350:1387-90.
20. Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008;68:889-92.
21. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
22. Gammon G, Shastri N, Cogswell J, et al. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev 1987;98:53-73.
23. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
24. Cibotti R, Kanellopoulos JM, Cabaniols JP, et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A 1992;89:416-20.
25. Cabaniols JP, Cibotti R, Kourilsky P, et al. Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol 1994;24:1743-9.
26. Theobald M, Biggs J, Hernández J, et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
27. Hernández J, Lee PP, Davis MM, et al. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000;164:596-602.
28. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004;113:425-33.
29. Moudgil KD, Sercarz EE. The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin Immunol Immunopathol 1994;73:283-9.
30. Moudgil KD, Southwood S, Ametani A, et al. The selfdirected T cell repertoire against mouse lysozyme reflects the influence of the hierarchy of its own determinants and can be engaged by a foreign lysozyme. J Immunol 1999;163:4232-7.
31. Boisgérault F, Anosova NG, Tam RC, et al. Induction of T-cell response to cryptic MHC determinants during allograft rejection. Hum Immunol 2000;61:1352-62.
32. Sinha P, Chi HH, Kim HR, et al. Mouse lysozyme-M knockout mice reveal how the self-determinant hierarchy shapes the T cell repertoire against this circulating self antigen in wild-type mice. J Immunol 2004;173:1763-71.
33. Friedman RS, Spies AG, Kalos M. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol 2004;34:1091-101.
34. Anderton SM, Viner NJ, Matharu P, et al. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 2002;3:175-81.
35. Naftzger C, Takechi Y, Kohda H, et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A 1996;93:14809-14.
36. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
37. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-64.
38. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
39. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-22.
40. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000;128:273-80.
41. Palomba ML, Roberts WK, Dao T, et al. CD8+ T-celldependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005;11:370-9.
42. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
43. Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000;30:3411-21.
44. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
45. Moudgil KD, Sercarz EE. Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: implications in shaping of the T cell repertoire and autoimmunity. J Exp Med 1993;178:2131-8.
46. Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 1998;93:192-9.
47. Fong L, Brockstedt D, Benike C, et al. Dendritic cellbased xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167:7150-6.
48. Srinivasan R, Houghton AN, Wolchok JD. Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun 2002;2:8.
49. Hawkins WG, Gold JS, Blachere NE, et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 2002;102:137-43.
50. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9:1284-90.
51. van Buuren MM, Calis JJ, Schumacher TN. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 2014;3:e28836.
52. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
53. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 1997;90:785-95.
54. Kumaki F, Kawai T, Hiroi S, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001;32:188-95.
55. Vetsika EK, Papadimitraki E, Aggouraki D, et al. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients. J Immunother 2011;34:641-50.
56. Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999;22:288-98.
57. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539-48.
58. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105:3849-54.
59. Kotsakis A, Vetsika EK, Christou S, et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol 2012;23:442-9.
60. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25:2727-34.
61. Mavroudis D, Bolonakis I, Cornet S, et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006;70:306-14.
62. Vetsika EK, Konsolakis G, Aggouraki D, et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother 2012;61:157-68.
63. Georgoulias V, Douillard JY, Khayat D, et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptidebased cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 2013;14:461-5.